What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and ubrogepant
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names ubrogepant in its contraindications section; the ubrogepant label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Drug Class: ubrogepant; Drugs within Class: ↑ ubrogepant; Effect on Concentration: Co-administration of ubrogepant with PAXLOVID is contraindicated due to potential for serious adverse reactions.”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the ubrogepant FDA label on DailyMed (effective June 5, 2025, Allergan, Inc.).
What does the nirmatrelvir/ritonavir label say about ubrogepant?
Nirmatrelvir/ritonavir label, contraindicationsMigraine medications: eletriptan, ubrogepant
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: ubrogepant; Drugs within Class: ↑ ubrogepant; Effect on Concentration: Co-administration of ubrogepant with PAXLOVID is contraindicated due to potential for serious adverse reactions [see ].
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the ubrogepant label say about nirmatrelvir/ritonavir?
Ubrogepant's label (effective June 5, 2025) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (UBRELVY), NDA211765 (Abbvie), as published by Allergan, Inc., effective June 5, 2025 (SPL set fd9f9458-fd96-4688-be3f-f77b3d1af6ab), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nirmatrelvir/ritonavir | Ubrogepant | |
|---|---|---|
| Labeled for | COVID-19 | Migraine |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $109.11 per tablet 100 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once